Ranifin®

Indication : For hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or as an alternative to the oral dosage form for short-term use in patients who are unable to take Ranitidine oral.

Composition : Each ml Ranifin® IV/IM Injection 50 mg/2 ml contains Ranitidine HCl equivalent to Ranitidine 25 mg.
Contain of excipients: Dibasic sodium phosphate dihydrate, Potassium phosphate monobasic, water for injection.

Presentation : Ranifin® IV/IM Injection 50 mg/2 ml
Box, 5 ampoules @ 2 ml

On medical prescription only.
Store below 25°C and dry place, protect from light